Vaš brskalnik ne omogoča JavaScript!
JavaScript je nujen za pravilno delovanje teh spletnih strani. Omogočite JavaScript ali pa uporabite sodobnejši brskalnik.
Nacionalni portal odprte znanosti
Odprta znanost
DiKUL
slv
|
eng
Iskanje
Brskanje
Novo v RUL
Kaj je RUL
V številkah
Pomoč
Prijava
Galectin-8 inhibition and functions in immune response and tumor biology
ID
Purić, Edvin
(
Avtor
),
ID
Nilsson, Ulf J.
(
Avtor
),
ID
Anderluh, Marko
(
Avtor
)
PDF - Predstavitvena datoteka,
prenos
(3,95 MB)
MD5: 1B946288E8E360D205A623A85016F73C
URL - Izvorni URL, za dostop obiščite
https://onlinelibrary.wiley.com/doi/10.1002/med.22041
Galerija slik
Izvleček
Galectins are among organisms' most abundantly expressed lectins (carbohydrate-binding proteins) that specifically bind β-galactosides. They act not only outside the cell, where they bind to extracellular matrix glycans, but also inside the cell, where they have a significant impact on signaling pathways. Galectin-8 is a galectin family protein encoded by the LGALS8 gene. Its role is evident in both T- and B-cell immunity and in the innate immune response, where it acts directly on dendritic cells and induces some pro-inflammatory cytokines. Galectin-8 also plays an important role in the defense against bacterial and viral infections. It is known to promote antibacterial autophagy by recognizing and binding glycans present on the vacuolar membrane, thus acting as a danger receptor. The most important role of galectin-8 is the regulation of cancer growth, metastasis, tumor progression, and tumor cell survival. Importantly, the expression of galectins is typically higher in tumor tissues than in noncancerous tissues. In this review article, we focus on galectin-8 and its function in immune response, microbial infections, and cancer. Given all of these functions of galectin-8, we emphasize the importance of developing new and selective galectin-8 inhibitors and report the current status of their development.
Jezik:
Angleški jezik
Ključne besede:
galectins
,
galectin-8
,
galectin-8 inhibitors
,
immune response
,
tumor
Vrsta gradiva:
Članek v reviji
Tipologija:
1.02 - Pregledni znanstveni članek
Organizacija:
FFA - Fakulteta za farmacijo
Status publikacije:
Objavljeno
Različica publikacije:
Objavljena publikacija
Leto izida:
2024
Št. strani:
Str. 2236-2265
Številčenje:
Vol. 44, iss. 5
PID:
20.500.12556/RUL-160174
UDK:
616-097:616-006
ISSN pri članku:
1098-1128
DOI:
10.1002/med.22041
COBISS.SI-ID:
192485379
Datum objave v RUL:
22.08.2024
Število ogledov:
218
Število prenosov:
67
Metapodatki:
Citiraj gradivo
Navadno besedilo
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Kopiraj citat
Objavi na:
Gradivo je del revije
Naslov:
Medicinal research reviews
Skrajšan naslov:
Med. res. rev.
Založnik:
Wiley
ISSN:
1098-1128
COBISS.SI-ID:
512824089
Licence
Licenca:
CC BY-NC 4.0, Creative Commons Priznanje avtorstva-Nekomercialno 4.0 Mednarodna
Povezava:
http://creativecommons.org/licenses/by-nc/4.0/deed.sl
Opis:
Licenca Creative Commons, ki prepoveduje komercialno uporabo, vendar uporabniki ne rabijo upravljati materialnih avtorskih pravic na izpeljanih delih z enako licenco.
Sekundarni jezik
Jezik:
Slovenski jezik
Ključne besede:
galektini
,
galektin-8
,
zaviralci galektina-8
,
imunski odziv
,
tumorji
Projekti
Financer:
ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:
P1-0208
Naslov:
Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin
Financer:
EC - European Commission
Program financ.:
H2020
Številka projekta:
765581
Naslov:
Multidisciplinary European Joint Doctorate in the Design and Development of Glyco Drugs
Akronim:
PhD4GlycoDrug
Podobna dela
Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:
Nazaj